Advertisement

PSN

, Volume 2, Issue 4, pp 25–31 | Cite as

Les médicaments thymorégulateurs et leurs associations dans le traitement des troubles bipolaires

  • Marc Louis Bourgeois
Thérapeutique

Résumé

Les médicaments dits thymorégulateurs sont efficaces à la fois sur les épisodes aigus maniaco-dépressifs et dans le traitement de maintenance prophylactique, réduisant les risques de récurrence. Un nombre limité de médicaments répondent (incomplètement) à cette définition: lithium, carbamazépine, acide valproïque, quelques médicaments anticonvulsivants, en particulier la lamotrigine par son effet anti-dépresseur prévalent et les antipsychotiques atypiques. Dans la pratique courante l’association de ces différentes molécules est la règle polutôt que l’exception.

Mots Clés

Thymorégulateurs Troubles bipolaires Associations thérapeutiques 

Association of mood stabilizers in the treatment of bipolar disorders

Abstract

Mood stabilizers are defined by their effectiveness on the various clinical aspects of bipolar episodes (mania, hypomania, depression, mixed states, rapid cycling etc.), and prophylaxis in the long-term course of the disorder. Only a few molecules have a proven efficacy to prevent or limit these disturbances: lithium, carbamazepine, valproic acid, lamotrigine and atypical antipsychotics. In clinical practice polypharmacy is the rule. We have to consider the rationale of these associations.

Keywords

Mood stabilizers Bipolar disorders Pharmacological association 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Angst J. 1998. The emerging epidemiology of hypomania and bipolar II disorder.J Affect Disord 50: 143–151PubMedCrossRefGoogle Scholar
  2. 2.
    Baldessarini R.J., Tondo L., Faedda G.L., Stuppes T.R., Floris G., Rudas N. 1996. Effects of the rate of discontinuing lithium maintenance treatment in bipolar disorder.J Clin Psychiatry 57: 441–448PubMedGoogle Scholar
  3. 3.
    Bourgeois M. L. 2000. Recognising the full spectrum of bipolar disorder.In Bowden C.L. (ed.).Diagnosis and Management of Bipolar Disorders. London: Science Press.Google Scholar
  4. 4.
    Bowden C.L.et al. 1994. Efficacy of divalproexvs lithium and placebo in the treatment of mania.JAMA 271: 918–924PubMedCrossRefGoogle Scholar
  5. 5.
    Bowden C.L. 2002. Pharmacological treatment of bipolar disorder: a review.In Maj M., Akiskal H. S., Lopez-Ibor J. J., Sartorius N. (eds).Bipolar disorder, WPA Series Evidence and Experience in Psychiatry. Chichester: John Wiley and Sons, p. 191–221 et commentaires p. 222–279.Google Scholar
  6. 6.
    Frye M. A.et al. 2000. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders.J Clin Psychopharmacol 20: 607–614.PubMedCrossRefGoogle Scholar
  7. 7.
    Goodwin G.M. 2000. Perspectives for clinical research on bipolar disorders in the new millennium.Bipolar Disorders 2: 302–304PubMedCrossRefGoogle Scholar
  8. 8.
    Hirschfeld R.M.A. 2000. Course and treatment of bipolar depression.In Bowden C.L. (ed.).Diagnosis and Management of Bipolar Disorders. London: Science Press.Google Scholar
  9. 9.
    Janowsky D.S., Morter S., Hong L., Howe L. 1999. Myers Briggs Type Indicator and Tridimensional Personality Questionnaire differences between bipolar patients and unipolar depressed patients.Bipolar Disorders 1: 98–108.PubMedCrossRefGoogle Scholar
  10. 10.
    Kasper S. 2002. Bipolar disorders: a new field for rational polypharmacy.In Maj M., Akiskal H. S., Lopez-Ibor J. J., Sartorius N. (eds).Bipolar disorder, WPA Series Evidence and Experience in Psychiatry. Chichester: John Wiley and Sons, p. 275–276.Google Scholar
  11. 11.
    Ketter A., Calabrese J.R. 2001. Stabilization of mood from below versus above baseline in bipolar disorder: A new nomenclature.J Clin Psychiatry 63: 146–151.Google Scholar
  12. 12.
    Sachs G.S. 1996. Treatment-resistant bipolar depression.Psychiatr Clin North Am 19: 215–236.PubMedCrossRefGoogle Scholar
  13. 13.
    Suppes T., Bladessarini R.J., Feadda G.L., Tohen M. 1991. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder.Arch Gen Psychiatry 48: 1082–1088.PubMedGoogle Scholar
  14. 14.
    Vieta E., Gasto C. 1997.Los trastornos bipolares. Barcelone: Springer Verlag Iberica.Google Scholar

Copyright information

© Springer 2004

Authors and Affiliations

  • Marc Louis Bourgeois
    • 1
  1. 1.Institut Pitres et RégisUniversité Victor Segalen Bordeaux 2 Hôpital Charles PerrensBordeaux Cedex

Personalised recommendations